Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases

SY Zhang, MJ Xu, X Wang - British journal of pharmacology, 2018 - Wiley Online Library
SY Zhang, MJ Xu, X Wang
British journal of pharmacology, 2018Wiley Online Library
Adrenomedullin (ADM) 2/intermedin (IMD) is a short peptide that belongs to the CGRP
superfamily. Although it shares receptors with CGRP, ADM and amylin, ADM2 has
significant and unique functions in the cardiovascular system. In the past decade, the
cardiovascular effect of ADM2 has been carefully analysed. In this review, progress in
understanding the effects of ADM2 on the cardiovascular system and its protective role in
cardiometabolic diseases are summarized. Linked Articles This article is part of a themed …
Adrenomedullin (ADM) 2/intermedin (IMD) is a short peptide that belongs to the CGRP superfamily. Although it shares receptors with CGRP, ADM and amylin, ADM2 has significant and unique functions in the cardiovascular system. In the past decade, the cardiovascular effect of ADM2 has been carefully analysed. In this review, progress in understanding the effects of ADM2 on the cardiovascular system and its protective role in cardiometabolic diseases are summarized.
Linked Articles
This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc
Wiley Online Library